T. Rowe Price Associates’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

T. Rowe Price Associates’s Portfolio OYST Stock Details OYST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-17,028	Closed	-$202K	–	3069
2021 Q3	$202K	Sell	17,028 -962	-5%	-$14K	﹤0.01%	2723
2021 Q2	$309K	Sell	17,990 -27,827	-61%	-$529K	﹤0.01%	2590
2021 Q1	$838K	Buy	+45,817	New	+$961K	﹤0.01%	2140

Other funds holding OYST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

T. Rowe Price Associates's OYST Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q4 2021, closing a stake of 17,028 shares — an estimated $202K sold.

T. Rowe Price Associates first reported a position in OYST in Q1 2021 and held it in 3 quarters. The position peaked at $838K in Q1 2021. 80 funds tracked by Wall St. Rank hold OYST as of Q4 2021.

T. Rowe Price Associates reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
T. Rowe Price Associates sold 17,028 Oyster Point Pharma, Inc. Common Stock shares in Q4 2021, an estimated $202K.
T. Rowe Price Associates first reported a position in Oyster Point Pharma, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
T. Rowe Price Associates's Oyster Point Pharma, Inc. Common Stock position peaked at $838K in Q1 2021.
80 funds tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.